Kiora Pharmaceuticals, Inc. (KPRX) Investor Relations Documents

Kiora Pharmaceuticals, Inc. (KPRX) investor relations documents from the company's IR site: 2 presentations, 23 press releases; latest deck 2026-02-26. Read in-app with summaries. First-party data.

Download Slides: Kiora Pharmaceuticals is developing KIO-301 for vision restoration in inherited retinal diseases and KIO-104 for retinal inflammation, with cash runway into late 2027.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-19Press releaseKiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun
2026-08-07Press releaseKiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-02Press releaseKiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
2026-06-18Press releaseKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Mo
2026-05-08Press releaseKiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-08Press releaseDownload as PDF
2026-04-14Press releaseKiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
2026-04-07Press releaseKiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
2026-04-02Press releaseKiora Pharmaceuticals Announces Management Team Changes
2026-03-25Press releaseKiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with
2026-02-26PresentationDownload Slides
2026-02-19Press releaseKiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
2026-01-27Press releaseRetinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
2025-04-04Press releaseKiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
2025-02-11Press releaseKiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Ed
2024-09-25Press releaseKiora Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-03-25Press releaseKiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
2023-11-09Press releaseKiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases
2023-08-08PresentationQ2 Business Update: View Kiora's Latest Presentation Detailing Our Sharpened Focus on Orphan Retinal Disease
2023-08-08Press releaseKiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Develop
2023-03-10Press releaseKiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
2022-11-09Press releaseEarnings Release HTML
2022-08-12Press releaseEarnings Release HTML
2022-04-15Press releaseEarnings Release HTML
2021-11-15Press releaseEarnings Release HTML

KPRX overview · KPRX earnings · KPRX financials · KPRX KPIs · KPRX ownership · KPRX peers · KPRX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.